Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets

Journal of Virology

Volumn 85, Issue 6, 2011, Pages 2851-2858

  Van Den Brand, Judith M A ^a   Kreijtz, Joost H C M ^a   Bodewes, Rogier ^a   Stittelaar, Koert J ^a,b   Van Amerongen, Geert ^a   Kuiken, Thijs ^a   Simon, James ^b   Fouchier, Ron A M ^a   Del Giudice, Giuseppe ^c   Rappuoli, Rino ^c   Rimmelzwaan, Guus F ^a,b   Osterhaus, Albert D M E ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Viroclinics Biosciences BV   (Netherlands)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; MIFAMURTIDE;

2009 H1N1 INFLUENZA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FERRET; IMMUNIZATION; INFLUENZA VACCINATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; VIRUS REPLICATION; VIRUS TITRATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BODY TEMPERATURE; BODY WEIGHT; DISEASE MODELS, ANIMAL; FEMALE; FERRETS; HISTOCYTOCHEMISTRY; IMMUNIZATION, SECONDARY; IMMUNOHISTOCHEMISTRY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; LUNG; MALE; MICROSCOPY; NOSE; ORTHOMYXOVIRIDAE INFECTIONS; PHARYNX; POLYSORBATES; SQUALENE; VACCINATION; VIRAL LOAD;

MUSTELA; ORTHOMYXOVIRIDAE; SUIDAE;

EID: 79952411472     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01939-10     Document Type: Article

References (28)

1. Ansaldi, F., et al. 2008. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 26:1525-1529.
2. Ansaldi, F., et al. 2010. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine 28:4123-4129.
3. Bosch, B. J., et al. 2010. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J. Virol. 84:10366-10374.
4. Carrat, F., and A. Flahault. 2007. Influenza vaccine: the challenge of antigenic drift. Vaccine 25:6852-6862. (Pubitemid 47398929)
5. Centers for Disease Control and Prevention. 2009. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb. Mortal. Wkly. Rep. 58:521-524.
6. Centers for Disease Control and Prevention. 2009. Prevention and control of seasonal influenza with vaccines, recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Morb. Mortal. Wkly. Rep. 58:1-52.
7. Clark, T. W., et al. 2009. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N. Engl. J. Med. 361:2424-2435.
8. Del Giudice, G., et al. 2009. Seasonal influenza vaccine provides priming for A/H1N1 immunization. Sci. Transl. Med. 1:12re1.
9. Durando, P., G. Icardi, and F. Ansaldi. 2010. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin. Biol. Ther. 10:639-651.
10. Forrest, H. L., et al. 2009. Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. Vaccine 27:4187-4195.
11. Frank, A. L., J. Puck, B. J. Hughes, and T. R. Cate. 1980. Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement. J. Clin. Microbiol. 12:426-432.
12. Galli, G., et al. 2009. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl. Acad. Sci. U. S. A. 106:7962-7967.
13. Garten, R. J., et al. 2009. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325:197-201.
14. Hancock, K., et al. 2009. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 361:1945-1952.
15. Igarashi, M., et al. 2010. Predicting the antigenic structure of the pandemic (H1N1) 2009 influenza virus hemagglutinin. PLoS One 5:e8553.
16. Khurana, S., et al. 2010. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2:15ra5.
17. Munster, V. J., et al. 2009. Pathogenesis and transmission of swine-origin 2009 A (H1N1) influenza virus in ferrets. Science 325:481-483.
18. Nichol, K. L. 2003. The efficacy, effectiveness, and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 21:1769-1775. (Pubitemid 36398371)
19. Nicholson, K. G., et al. 2001. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357:1937-1943. (Pubitemid 32568336)
20. O'Hagan, D. T., A. Wack, and A. Podda. 2007. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? Clin. Pharmacol. Ther. 82:740-744.
21. Palmer, D., W. Dowle, M. Coleman, and G. Schild. 1975. Hemagglutination inhibition test, p. 25-62. In Advanced laboratory techniques for influenza diagnosis: procedural guide. U.S. Department of Health Education, Atlanta, GA.
22. Rimmelzwaan, G. F., M. Baars, E. C. Claas, and A. D. Osterhaus. 1998. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus, and immunofluorescence as methods for monitoring influenza virus replication in vitro. J. Virol. Methods 74:57-66.
23. Rimmelzwaan, G. F., et al. 2001. Antigenic and genetic characterization of swine influenza A (H1N1) viruses isolated from pneumonia patients in The Netherlands. Virology 282:301-306. (Pubitemid 32881157)
24. Skowronski, D. M., et al. 2010. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. PLoS Med. 7:e1000258.
25. Stephenson, I., et al. 2005. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 191:1210-1215.
26. van den Brand, J. M., et al. 2010. Severity of pneumonia due to new H1N1 influenza virus in ferrets is intermediate between that due to seasonal H1N1 virus and highly pathogenic avian influenza H5N1 virus. J. Infect. Dis. 201:993-999.
27. Webb, S. A., I. M. Seppelt, and A. I. Investigators. 2009. Pandemic (H1N1) 2009 influenza ("swine flu") in Australian and New Zealand intensive care. Crit. Care Resusc. 11:170-172.
28. World Health Organization. 2010. Pandemic (H1N1) 2009-update 97. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/don/2010-04- 23a/en/index.html.